PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
Synapse
⌘+K
Synapse
January 23, 2026Journal of Crohn s and Colitis

P0167Variation of serum advanced glycation end products after biological therapy in Inflammatory Bowel Disease

View Full Paper
Ask AI
Bookmark
Share

Authors

EVEva VissersJWJudith WellensCCClara Caenepeel

Discussion

Loading...

Member takes

Overview

Retrospective analysis explores serum AGEs and biological therapy response in inflammatory bowel disease, suggesting different roles in patient types.

Key Points

  • This study aims to investigate the relationship between serum advanced glycation end products (AGEs) and disease activity in inflammatory bowel disease (IBD) patients undergoing biological therapy.
  • Retrospective analysis of IBD patients initiating biological therapy (n = 75).
  • Endoscopic evaluation used at week 14 for ulcerative colitis (UC) and week 24 for Crohn’s disease (CD).
  • Three AGEs measured in serum via mass spectrometry: CML, MG-H1, and Pyr.
  • At baseline, serum MG-H1 was lower in UC patients compared to CD patients (p = 0.0001).
  • Levels of CML and MG-H1 decreased in CD patients after therapy (CML: p = 0.0495, MG-H1: p = 0.0432).
  • In UC patients, MG-H1 negatively correlated with C-reactive protein and endoscopic Mayo score.

Cite This Study

Vissers et al. (2026) studied this question.

synapsesocial.com/papers/69730fe2c8125b09b0d1f97bhttps://doi.org/10.1093/ecco-jcc/jjaf231.348
View Full Paper
Ask AI
Bookmark
Share